How food affects ECC4703 and how different formulations are absorbed in healthy adults.

A Phase I, Open-Label, Randomized, Single-Dose, Crossover Study to Evaluate Food Effect and Relative Bioavailability of ECC4703 Formulations (F0, F1, F2, and F3) in Healthy Adults

This trial will test how eating and different pill formulations change how ECC4703 is absorbed in healthy adults.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Eccogene (Industry-sponsored)
• Locations: 1 site (Adelaide, South Australia)
• Trial ID: NCT07334080 on ClinicalTrials.gov

What this trial studies

This is an open-label, randomized, single-dose Phase 1 pharmacokinetic study in healthy adult participants. Part 1 uses three cohorts (16 participants each) in a two-period crossover to measure food effects on three ECC4703 formulations (F1, F2, F3). Part 2 will enroll about 24 participants in an adaptive comparison of selected formulations versus the reference formulation F0, with finalized sequences, periods, and food conditions determined adaptively. Blood sampling for drug levels will be used to compare relative bioavailability and the impact of fed versus fasted states.

Who should consider this trial

Good fit: Healthy adults aged 18–65 with BMI 18.0–32.0 kg/m2 who meet weight, pregnancy testing, and contraception requirements and are not taking interfering medications are eligible.

Not a fit: People with active liver disease, other significant health conditions, pregnant or breastfeeding individuals, or those outside the age or BMI limits are unlikely to receive direct benefit from participation.

Why it matters

Potential benefit: If successful, this work could identify the best ECC4703 formulation and dosing conditions to support later trials aimed at treating metabolic dysfunction-associated steatohepatitis.

How similar studies have performed: Food-effect and relative bioavailability crossover studies are a standard approach that has informed formulation and dosing decisions for many drugs, but ECC4703 itself is novel and not yet proven effective for MASH.

Eligibility criteria

Inclusion Criteria:

* Healthy male and female participants
* Age of 18 to 65 years
* BMI of 18.0 to 32.0 kg/m2 with a minimum body weight of 50.0 kg (110 lb) for males and 45.0 kg (99 lb) for females.
* Female participants of childbearing potential must have negative serum pregnancy test at screening and a negative serum or urine pregnancy test prior to the first dose of study drug; use at least 1 highly effective method of contraception (e.g., hormonal contraception, intrauterine device, bilateral tubal occlusion, or vasectomized partner with confirmed success) during the study and for at least 90 days after the last dose of study drug; and refrain from egg donation or fertility treatments during the same period.
* Female participants who are postmenopausal, confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence
* Male participants agree to use contraception, or agree to practice true abstinence
* Not taking any medication within 14 days (or at least 5 half-lives whichever is longer) prior to Day 1 dosing, with the exception of stable-dose contraception, stable-dose hormonal replacement therapy, paracetamol at up to 2 g/day; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments.
* No clinically significant findings in physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, clinical laboratory evaluations, concomitant medications, or medical/psychiatric history
* Able to understand and sign and date informed consent

Exclusion Criteria:

* Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 90 days after the study.
* Concomitant participation in any investigational study of any nature
* Blood loss of ≥470 mL for non-physiological reasons (i.e., trauma, blood collection, blood donation) within 3 months prior to the first dose of study drug, plasma donation within 2 weeks prior to the first dose, platelet donation within 6 weeks prior to the first dose, or plans to donate blood during this study or within 1 month after the last dose of study drug.
* Clinically relevant acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic systems
* Significant allergic reaction to active ingredients or excipients of the study drug
* Regularly uses tobacco or nicotine products, including e-cigarettes (\>5 times per week) or has stopped using regular tobacco or nicotine products within the past 2 months.
* Unwilling to abstain from alcohol-containing products and/or xanthine/caffeine-containing products, including any food and beverages, within 48 hours prior to admission to the CRU on Day -1.
* Unwilling to abstain from grapefruit, grapefruit juice, and Seville oranges from 7 days prior to check-in on Day -1 until after their final follow-up visit.
* Unable to refrain from the use of any over-the-counter medications, prescription medications, nutritional supplements, or herbal medicines during the study, except for stable-dose contraception, stable-dose hormonal replacement therapy, paracetamol at up to 2 g/day; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments.
* Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study.
* Has had clinically significant interventional therapies and/or hospitalization (surgery, paracentesis, etc.) within 6 months prior to the study, or plans to have any surgeries during the duration of the study.

Where this trial is running

Adelaide, South Australia

• CMAX Clinical Research Pty Ltd — Adelaide, South Australia, Australia (Recruiting)

Study contacts

• Study coordinator: Eccogene Clinical Trials

Conditions Metabolic Dysfunction-Associated Steatohepatitis